Compounding Pharmacies — 503A Retail and 503B Outsourcing Facilities

Pharmaceutical compounding — the preparation of customized medications for individual patients — fills a critical gap in the commercial drug supply. For the FDA approval process that commercial drugs go through — which compounded drugs bypass — see FDA drug approval. For the generic drug pathway that provides lower-cost alternatives when commercial drugs are available, see generic drugs and the Hatch-Waxman Act. For patients who need a drug in a formulation that is not commercially available (different strength, alternative dosage form, without an allergen, or a combination product), compounding provides an essential service. Approximately 3–4% of all prescriptions filled in the United States involve some form of compounding. But compounding also carries serious risks: compounded drugs skip the FDA approval process that ensures commercial drugs are safe, effective, and manufactured to quality standards. The 2012 fungal meningitis outbreak — caused by contaminated steroid injections produced by the New England Compounding Center (NECC), killing 64 people and sickening over 750 — revealed the catastrophic potential of inadequate oversight of large-scale compounders and drove Congress to create a new regulatory framework. The Drug Quality and Security Act of 2013 (DQSA) established the current two-tier compounding structure: 503A (traditional retail pharmacy compounding for individual patient prescriptions) and 503B (large-scale outsourcing facilities that produce drugs in bulk without individual prescriptions). The boundary between these two tiers — and the question of when a compounder crosses from legitimate patient-specific compounding into unauthorized drug manufacturing — remains one of the most litigated areas of FDA pharmaceutical law.

Current Law (2026)

503A — Traditional Retail Pharmacy Compounding

Section 503A (21 U.S.C. § 353a) governs compounding by licensed pharmacists or physicians for individual patient prescriptions. A 503A compounder is exempt from FDA's drug approval requirements, cGMP manufacturing standards, and labeling requirements only if:

1. Prescription requirement: The compounded drug is prepared for an individually identified patient based on a valid prescription from a licensed practitioner (not in advance of receiving a prescription, with narrow exceptions)
2. Bulk drug substances: The compounder uses only bulk drug substances that: (a) appear on FDA's 503A bulks list (categories for which there is a clinical need), (b) are not copies of commercially available FDA-approved drugs (except in limited circumstances), and (c) are not withdrawn from the market for safety reasons
3. State licensure: The pharmacy and pharmacist are licensed by the state
4. Not interstate commerce in large quantities: Limited quantities shipped outside the state (though interstate compounding is common and subject to ongoing legal debate)
5. No advertising: The compounder does not advertise or promote specific compounded drugs to the general public

Under 503A, state pharmacy boards retain primary oversight authority — they inspect pharmacies, license pharmacists, and set practice standards. FDA's role over 503A pharmacies is secondary and focused on safety alerts, enforcement against clearly unsafe conditions, and maintaining the bulk drug substance list.

503B — Outsourcing Facilities

Section 503B (21 U.S.C. § 353b) created a new category of compounder — the registered outsourcing facility — for large-scale compounding operations that supply hospitals, clinics, and health systems with sterile drugs in bulk. 503B facilities:

• Voluntarily register with FDA (registration is not mandatory, but operating without registration means the facility must comply with all FDA drug approval requirements — effectively making registration the only viable option for large-scale compounders)
• May compound without patient-specific prescriptions — they can produce drugs "office stock" for healthcare facilities
• Must comply with current Good Manufacturing Practice (cGMP) regulations applicable to conventional drug manufacturers
• Are subject to FDA inspection under the same standards as conventional pharmaceutical manufacturers
• May not compound commercially available drugs in essentially the same formulation as the approved product, except under specific shortage conditions

503B facilities serve the hospital and health system market — producing compounded sterile preparations (IV solutions, injectable drugs, eye drops) at scale for facilities that use high volumes of drugs not available commercially, or that need customized concentrations or combinations.

The NECC Meningitis Outbreak — Why This Matters

Before DQSA, there was no clear regulatory category for large-scale compounders like the New England Compounding Center (NECC). NECC was licensed as a retail pharmacy under Massachusetts state law, but functioned as a national drug manufacturer — shipping compounded methylprednisolone acetate (a steroid injection for back pain) to pain clinics across the country without patient-specific prescriptions, without FDA oversight, and without cGMP manufacturing standards.

In 2012, NECC's steroid injections were contaminated with Exserohilum rostratum fungus. 64 people died from fungal meningitis and 750+ were injured in one of the worst pharmaceutical disasters in U.S. history. NECC had been inspected by Massachusetts regulators but the state lacked resources for the level of manufacturing oversight the operation required. FDA had identified concerns with NECC years earlier but lacked clear authority over it as a pharmacy.

DQSA was a direct legislative response, creating 503B to bring large-scale compounders into a federal regulatory framework with cGMP requirements and FDA inspection authority.

Commercially Available Drug Exemption — The "Copy" Problem

Both 503A and 503B prohibit compounding a drug that is commercially available and essentially a copy of the approved product. This restriction exists to prevent compounders from undercutting FDA-approved drugs by producing cheaper, non-FDA-approved copies — which would undermine the approval system and expose patients to non-cGMP products.

Exceptions:

• A drug that is on FDA's drug shortage list may be compounded even if it is commercially available
• A patient has a documented medical need for a difference in the commercially available product (e.g., different strength, formulation, allergen removal, route of administration)
• A prescriber documents that the patient requires the compounded version

The "commercially available" restriction is one of the most litigated aspects of compounding law. Compounders and prescribers frequently argue that patient-specific needs justify compounding what is otherwise a commercially available drug.

Drug Shortages and Compounding

FDA's drug shortage list (maintained under 21 U.S.C. § 356c) directly interacts with compounding law. During a shortage of an FDA-approved drug:

• Both 503A and 503B compounders may prepare compounded versions of the shortage drug
• 503B outsourcing facilities specifically serve an important role in supplying hospitals during shortages of injectable drugs

The COVID-19 pandemic and subsequent supply chain disruptions created significant drug shortages, leading to expanded compounding under shortage provisions and ongoing FDA guidance on what could be compounded.

How It Affects You

If you need a compounded medication: Compounded drugs are appropriate when you have a genuine clinical need that cannot be met by a commercially available product — a child who needs a liquid formulation of a drug only available in pills, a patient allergic to a dye or preservative in the commercial formulation, or a patient who needs a combination product not commercially produced. Ask your prescriber to document the medical necessity for compounding on the prescription; this is required for 503A compliance and protects both you and your pharmacy. If your physician is prescribing a compounded version of a drug that is commercially available without a documented clinical reason, ask why — you may be receiving a product that falls outside the legal scope of compounding and lacks the quality guarantees of an FDA-approved drug.

If you are receiving compounded sterile injections (joint injections, IV medications): Ask whether the product comes from a 503A retail pharmacy or a 503B registered outsourcing facility. You can check FDA's list of registered 503B outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities — these facilities are subject to cGMP manufacturing standards and FDA inspection. Products from 503A retail pharmacies are not manufactured under the same standards; for sterile injectables in particular, this distinction matters for safety. If a clinic or pain management practice is using sterile injectables from an unregistered compounder, this is a red flag worth raising.

If you use hormone replacement therapy (HRT) or bioidentical hormone compounds: Compounded bioidentical hormones (cBHT) — customized hormone preparations compounded for individual patients — are commonly prescribed and represent one of the largest categories of compounded drugs by volume. These products are not FDA-approved; their safety and efficacy have not been established through the approval process. FDA has expressed concern that some compounded cBHT preparations claim benefits (disease prevention, "natural" superiority over approved hormones) without clinical evidence. If you use compounded hormones, ensure your prescriber has documented your specific clinical need for compounding rather than using an FDA-approved hormone therapy.

If you are a healthcare administrator or formulary manager: Verify that compounded sterile preparations your facility purchases come from registered 503B outsourcing facilities — this is the only category of large-scale compounder subject to FDA cGMP oversight. Maintain records of the lot numbers and suppliers of compounded drugs used in your facility; in the event of a contamination event, these records are essential for rapid patient notification and treatment. Review your state's pharmacy board requirements for compounding — state laws vary and may be more restrictive than federal minimums.

State vs. Federal Jurisdiction

Compounding regulation is a shared federal-state system:

• State pharmacy boards license pharmacists and pharmacies, set practice standards, and inspect 503A facilities
• FDA has primary jurisdiction over 503B registered outsourcing facilities and secondary jurisdiction over 503A pharmacies for safety violations
• States may be more restrictive than federal law (e.g., prohibiting certain bulk substances or interstate shipping) but cannot be less restrictive
• The interstate shipping of compounded drugs by 503A pharmacies is subject to both state and federal law; FDA has issued guidance but some aspects remain legally contested

Pending Issues and Recent Developments

• GLP-1 receptor agonists and compounding: The dramatic demand for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) for weight management created drug shortages, allowing 503A and 503B compounders to produce these drugs legally under shortage provisions. When FDA removed these drugs from the shortage list in 2024–2025, FDA directed compounders to cease production — leading to significant legal challenges from compounders, prescribers, and patients who had been using compounded versions. The litigation and regulatory guidance around GLP-1 compounding is an active and evolving area
• 503A bulks list: FDA continues to add and remove substances from the list of bulk drug substances that may be used in 503A compounding; each listing or delisting generates industry comment and occasional litigation
• Veterinary compounding: Veterinary drug compounding operates under a separate framework (Animal Medicinal Drug Use Clarification Act and FDA guidance); companion animal and agricultural compounding have different rules than human drug compounding
• Oversight gaps: Inspector General reports have noted gaps in both FDA and state pharmacy board oversight of compounders; the NECC-driven reforms improved oversight of large-scale sterile compounders significantly, but smaller operations and non-sterile compounders remain primarily under state jurisdiction with variable oversight quality